ClinicalTrials.gg
RecruitingNCT06544018ICARUSUpdated Feb 27, 2026

Circadian Rhythm Deregulation in Patients With CAPS

An interventional study of Genetic analysis of NLRP3 and Circadian rhythm measurement in Cryopyrin Associated Periodic Syndrome, Familial Cold Urticaria and Muckle-Wells Syndrome, sponsored by Hospices Civils de Lyon. Recruiting at 6 sites in France. Open to participants aged 6 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Cryopyrin-Associated Periodic Syndromes with a site in France — 2 open to participants now, 2 under way, none of them phase 3. Cryopyrin-Associated Periodic Syndromes · France.

Started
2026
the only one that year
No phase
Only one
of the 10
Registered
10th of 10
by date
Lead sponsor
1 of 10
Hospices Civils de Lyon

Among the 10 studies in Cryopyrin-Associated Periodic Syndromes with a site in France, this one is the only one that started in 2026, is the only one with no phase, and was the 10th registered.

Cryopyrin-Associated Periodic Syndromes

35 studies on the registry are indexed under Cryopyrin-Associated Periodic Syndromes; 5 are open to participants now.

Browse Cryopyrin-Associated Periodic Syndromes studies →

Open to participants now

2 of the 10 studies in Cryopyrin-Associated Periodic Syndromes with a site in France are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 4 Cryopyrin-Associated Periodic Syndromes studies recruiting now, 1 sets no upper age limit and none stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 6 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Cryopyrin-Associated Periodic Syndromes with a site in France, or all of them as a file.
02

Study summary

Circadian rhythms are characterized by the physiology's adaptation to the alternation of day and night, enabling to adapt to the environment. These rhythms are generated by a molecular clock within each cell. At the molecular level, the circadian clock is based on a complex system of cell-autonomous transcription loops. These exert positive and negative feedback on themselves, generating cyclic transcriptional activity.

  • In the main loop, the BMAL1 transcription factor links with CLOCK or NPAS2 ( (Neuronal PAS Domain Protein 2) to activate transcription of per1,2 and 3 and cryptochrome (cry1 and cry2), which in turn repress BMAL1/CLOCK1 transcriptional activity.. The BMAL1/CLOCK complex also activates transcription of numerous target genes (per and cry, Rev-erb, etc.)..
  • other secondary loops refine the function of the first.

Recent studies suggest that many aspects of innate immunity are controlled by circadian rhythm through inhibition of NLRP3 inflammasome activation. Nevertheless, the regulation of the NLRP3 inflammasome by the circadian clock has yet to be elucidated. Inflammasomes are molecular platforms that control caspase-1 activation and consequently the maturation of precursors of (interleukine) IL-1β, pro-IL-18, a pro-inflammatory cytokine. Since its discovery, its functions have been widely characterized as part of the innate immune response as a sensor of pathogens and danger signals (extracellular ATP (Adenosine triphosphate), atmospheric pollutants). NLRP3 (nucleotide-binding domain LRR (leucin-rich repeat ) and pyrin-containing receptor 3) has been described for its genetic association with dominant monogenic hereditary syndromes characterized by recurrent systemic inflammatory episodes in the absence of any infection or autoimmune disease, known as CAPS (cryopyrin-associated periodic syndrome) or cryopyrinopathies which is a continuum of diseases ranging from a moderate to the most severe form of the syndrome: familial cold urticaria syndrome, Muckle-Wells syndrome (MWS), and CINCA/NOMID syndrome.

Interestingly, patients with Muckle-Wells syndrome show a circadian pattern of symptoms, with a recurrent, predominantly vesperal fever peak lasting a few hours, and extreme fatigue on a daily basis. However, a molecular link between the circadian clock and CAPS pathology remains to be determined.

The aim of this protocol is to identify circadian rhythm dysregulation in patients with CAPS confirmed by genetic analysis of NLRP3, to demonstrate a link between circadian clock and CAPS syndrome, and to identify circadian clock regulatory pathways.

03

Conditions studied

  • Cryopyrin Associated Periodic Syndrome
  • Familial Cold Urticaria
  • Muckle-Wells Syndrome
  • CINCA Syndrome

Keywords

  • Circadian clock
  • cryopyrin-associated periodic syndrome
  • familial cold urticaria
  • muckle-wells syndrome
  • melatonin
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient with CAPS group :

  • Patients aged 6 and over
  • Participant with CAPS confirmed by NLRP3 genetic analysis
  • Weight greater than or equal to 25 Kg
  • Parents/guardians who have been informed of the study and have signed a consent form.
  • Patient affiliated to a social security scheme

Control group (healthy participant):

  • Participant aged 6 and over
  • Weight greater than or equal to 25 Kg
  • Participant living in the same household as a subject with CAPS genetically confirmed by NLRP3 analysis and included in the protocol
  • Participant with no CAPS (a priori) who consents to NLRP3 genetic analysis
  • Parents/guardians who have been informed of the study and have signed a consent form.
  • Participant who has been informed of the study and has agreed to take part
  • Participant affiliated to a social security scheme

Exclusion criteria

  • Exclusion Criteria :

Patient with CAPS group :

  • Patients with chronic sleep disorders (narcolepsy, hypersomnia) requiring medication (sleeping pills, melatonin).
  • Patients with sleep apnea syndrome
  • Patients working regular night shifts or alternating day and night shifts
  • Pregnant or breast-feeding women
  • Parents with an infant under 6 months of age
  • Patient participating in another interventional drug study
  • Deprivation of civil rights (curators, guardianship, safeguard of justice)

Control group (healthy participant):

  • Participants with a chronic illness (ALD beneficiaries)
  • Participants with chronic sleep disorders (narcolepsy, hypersomnia) requiring medication (sleeping pills, melatonin)
  • Participants working regular night shifts or alternating day and night shifts
  • Pregnant or breast-feeding women
  • Parents with an infant under 6 months of age
  • Participant participating in another interventional drug study
  • Deprivation of civil rights (curators, guardianship, safeguard of justice)
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Patients with cryopyrin-associated periodic syndrome (CAPS)

    Confirmed by genetic analysis of NLRP3

    Genetic: Genetic analysis of NLRP3 · Device: Circadian rhythm measurement · Biological: Saliva sampling · Other: Questionnaire · Other: AIDAI score · Biological: Blood sampling

  • Placebo comparator
    Control group

    Healthy participant (absence of CAPS, verified by NLRP3 gene analysis) living in the same household as a CAPS participant included in the protocol

    Genetic: Genetic analysis of NLRP3 · Device: Circadian rhythm measurement · Biological: Saliva sampling · Other: Questionnaire · Biological: Blood sampling

Interventions

  • GeneticGenetic analysis of NLRP3

    Blood test for genetic analysis of NLRP3

  • DeviceCircadian rhythm measurement

    Wear a Withings Pulse HR (heart rate) actigraphic watch 24 hours a day for 1 month to define circadian rhythm

  • BiologicalSaliva sampling

    Saliva sampling for salivary melatonin determination

  • OtherQuestionnaire

    Questionnaire to determine chronotype

  • OtherAIDAI score

    Disease activity score using AIDAI score (only for patients in the CAPS group) AIDAI : AUTO-INFLAMMATORY DISEASE ACTIVITY INDEX

  • BiologicalBlood sampling

    1. Inflammatory cytokines measurement : IL1-beta (Interleukin-1) and IL-18. 2. Molecular characterization of circadian clock signaling pathways

06

What researchers measure

Primary outcomes

  1. Description of circadian rhythm deregulation in patients with cryopyrinopathy (CAPS) whose diagnosis was confirmed by genetic analysis of NLRP3,

    Concentration of the peak secretion of melatonin in both arms

    Time frame: 6 months after inclusion

  2. Description of circadian rhythm deregulation in patients with cryopyrinopathy (CAPS) whose diagnosis was confirmed by genetic analysis of NLRP3,

    Concentration of the peak secretion of melatonin in both arms

    Time frame: 12 months after inclusion

  3. Description of circadian rhythm deregulation in patients with cryopyrinopathy (CAPS) whose diagnosis was confirmed by genetic analysis of NLRP3,

    time of the peak secretion of melatonin in both arms

    Time frame: 6 months after inclusion

  4. Description of circadian rhythm deregulation in patients with cryopyrinopathy (CAPS) whose diagnosis was confirmed by genetic analysis of NLRP3,

    time of the peak secretion of melatonin in both arms

    Time frame: 12 months after inclusion

Secondary outcomes

  1. Difference in circadian clock biomarkers between patients and control participants for Circadian Rhythm Characteristics.

    Determination of circadian rhythms : amplitude in both arms

    Time frame: 6 th month

  2. Difference in circadian clock biomarkers between patients and control participants for Circadian Rhythm Characteristics.

    Determination of circadian rhythms : period in both arms

    Time frame: 6 th month

  3. Difference in circadian clock biomarkers between patients and control participants for Circadian Rhythm Characteristics.

    Determination of circadian rhythms : phase in both arms

    Time frame: 6 th month

  4. Chronotype determination

    Number of patients in each chronotype for the 2 arms based on the specific questionnaire in both arm

    Time frame: 6 th month

  5. sleep duration

    sleep duration in both arms

    Time frame: 6 th month

  6. number of steps

    Daily activity in both arms

    Time frame: 6 th month

  7. Comparison of inflammatory state

    basal levels of IL1β in patient monocytes in both arms

    Time frame: 6 months after inclusion

  8. Comparison of inflammatory state

    basal levels of IL1β in patient monocytes in both arms

    Time frame: 12 months after inclusion

  9. Comparison of inflammatory state

    basal levels of IL18 in patient monocytes in both arms

    Time frame: 6 months after inclusion

  10. Comparison of inflammatory state

    basal levels of IL18 in patient monocytes in both arms

    Time frame: 12 months after inclusion

  11. Disease activity measurement

    Number of patient with active disease ie AIDAI (AUTO-INFLAMMATORY DISEASE ACTIVITY INDEX) score \>9 in CAPS patient arm

    Time frame: 6 months after inclusion

  12. Disease activity measurement

    Number of patient with active disease ie AIDAI (AUTO-INFLAMMATORY DISEASE ACTIVITY INDEX) score \>9 in CAPS patient arm

    Time frame: 12 months after inclusion

  13. presence or absence of an abnormality in the NLRP3 signalling pathway in CAPS arm compared control arm

    Biochemical characterization of the NLRP3 inflammasome protein regulatory pathway in both arms

    Time frame: 6 months after inclusion

  14. presence or absence of an abnormality in the NLRP3 signalling pathway in CAPS arm compared to control arm

    Biochemical characterization of the NLRP3 inflammasome protein regulatory pathway in both arms

    Time frame: 12 months after inclusion

  15. presence or absence of ASC inflammasome protein regulatory pathway in CAPs arm compared to control arm

    Biochemical characterization of the ASC inflammasome protein regulatory pathway in both arms

    Time frame: 6 months after inclusion

  16. presence or absence of ASC inflammasome protein regulatory pathway in CAPS arm compared to control arm

    Biochemical characterization of the ASC inflammasome protein regulatory pathway in both arms

    Time frame: 12 months after inclusion

  17. presence or absence of the CASPASE-1 inflammasome protein regulatory pathway in CAPS arm compared to control arm

    Biochemical characterization of the CASPASE-1 inflammasome protein regulatory pathway in both arms

    Time frame: 6 months after inclusion

  18. presence or absence of the CASPASE-1 inflammasome protein regulatory pathway in CAPS arm compared to control arm

    Biochemical characterization of the CASPASE-1 inflammasome protein regulatory pathway in both arms

    Time frame: 12 months after inclusion

  19. presence or absence of REV-ERBα inflammasome protein regulatory pathway in CAPS arm compared to control arm

    Biochemical characterization of the REV-ERBα inflammasome protein regulatory pathway in both arms

    Time frame: 6 months after inclusion

  20. presence or absence of REV-ERBα inflammasome protein regulatory pathway in CAPS arm compared to control arm

    Biochemical characterization of the REV-ERBα inflammasome protein regulatory pathway in both arms

    Time frame: 12 months after inclusion

07

Study locations

1 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Feb 2029, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2024
First posted
Aug 9, 2024
StartActual
Feb 25, 2026
Primary completionEst.
Feb 25, 2029
CompletionEst.
Feb 25, 2029
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06544018
Responsible party
Sponsor
First posted
Aug 9, 2024
Start date
Feb 25, 2026
Primary completion
Feb 25, 2029 (estimated)
Completion
Feb 25, 2029 (estimated)
Last update
Feb 27, 2026

Study contacts

Alexandre Alexandre, PR
Contact
Alexandre.belot@chu-lyon.fr
04 27 85 61 26 ext. 33
Samira Plassart
Contact
Samira.plassart@chu-lyon.fr
04 27 85 54 42 ext. 33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion